Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review

Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1051305
Main Authors Song, Yuanbin, Chen, Shuzhao, Liu, Chenfei, Chen, Lezong, Wang, Weida, Wu, Bingyi, Liang, Yang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.02.2023
Subjects
anti-programmed cell death protein 1
case report
chemo-free maintenance therapy
histone deacetylase inhibitor
literature review
Pharmacology
T-cell acute lymphoblastic leukemia
case report
anti-programmed cell death protein 1
chemo-free maintenance therapy
literature review
histone deacetylase inhibitor
T-cell acute lymphoblastic leukemia
Online AccessGet full text

Cover

Abstract Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the modern age, chemo-free maintenance therapy regimens for patients with T-ALL may dramatically improve the maintenance therapeutic landscape. We report here the combination of Anti-programmed cell death protein 1 antibody and histone deacetylase inhibitor as chemo-free maintenance treatment in a T-ALL patient with literature review, thus providing a unique perspective in addition to valuable information which may inform novel therapeutic approaches.
AbstractList Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the modern age, chemo-free maintenance therapy regimens for patients with T-ALL may dramatically improve the maintenance therapeutic landscape. We report here the combination of Anti-programmed cell death protein 1 antibody and histone deacetylase inhibitor as chemo-free maintenance treatment in a T-ALL patient with literature review, thus providing a unique perspective in addition to valuable information which may inform novel therapeutic approaches.
Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the modern age, chemo-free maintenance therapy regimens for patients with T-ALL may dramatically improve the maintenance therapeutic landscape. We report here the combination of Anti-programmed cell death protein 1 antibody and histone deacetylase inhibitor as chemo-free maintenance treatment in a T-ALL patient with literature review, thus providing a unique perspective in addition to valuable information which may inform novel therapeutic approaches.Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the modern age, chemo-free maintenance therapy regimens for patients with T-ALL may dramatically improve the maintenance therapeutic landscape. We report here the combination of Anti-programmed cell death protein 1 antibody and histone deacetylase inhibitor as chemo-free maintenance treatment in a T-ALL patient with literature review, thus providing a unique perspective in addition to valuable information which may inform novel therapeutic approaches.
Author Liu, Chenfei
Wu, Bingyi
Song, Yuanbin
Chen, Shuzhao
Chen, Lezong
Wang, Weida
Liang, Yang
AuthorAffiliation Department of Hematologic Oncology , State Key Laboratory of Oncology in South China , Collaborative Innovation Center for Cancer Medicine , Sun Yat-sen University Cancer Center , Guangzhou , China
AuthorAffiliation_xml – name: Department of Hematologic Oncology , State Key Laboratory of Oncology in South China , Collaborative Innovation Center for Cancer Medicine , Sun Yat-sen University Cancer Center , Guangzhou , China
Author_xml – sequence: 1
  givenname: Yuanbin
  surname: Song
  fullname: Song, Yuanbin
– sequence: 2
  givenname: Shuzhao
  surname: Chen
  fullname: Chen, Shuzhao
– sequence: 3
  givenname: Chenfei
  surname: Liu
  fullname: Liu, Chenfei
– sequence: 4
  givenname: Lezong
  surname: Chen
  fullname: Chen, Lezong
– sequence: 5
  givenname: Weida
  surname: Wang
  fullname: Wang, Weida
– sequence: 6
  givenname: Bingyi
  surname: Wu
  fullname: Wu, Bingyi
– sequence: 7
  givenname: Yang
  surname: Liang
  fullname: Liang, Yang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36873995$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1DAUjVARLaU_wAJ5ySaDH3nYLJCqEY9KldiUtXXt3HRcnDg4TtH8PU5nqFoWeGP7-pxzHz6vi5MxjFgUbxndCCHVh37aQdxwysWG0ZoJWr8ozljTiFJJxk-enE-Li3m-o3kJpURTvSpORSPbfKnPimm7wyGUfUQkA7gx4QijRZJ2GGHaEzcS6BafyE1p0XsCdklI_H6YdsF4mJOzxOPyEwcHH8klsTAjiTiFmAiMHfEuZaG0xDV67_D3m-JlD37Gi-N-Xvz48vlm-628_v71ant5Xdqqkam0opfM1AoEswr6rhJQN7Q1rWK16ZXknHedsH2LlTQtUlUZRaGqwPQVb3Or58XVQbcLcKen6AaIex3A6YdAiLcaYq7eo64tBdMYC4yKqm-MajnWQoGpJZWykVnr00FrWsyAncUxRfDPRJ-_jG6nb8O9Vnn-TVVngfdHgRh-LTgnPbh5nSeMGJZZ81aK3JnkLEPfPc31mOTvl2UAPwBsDPMcsX-EMKpXa-gHa-jVGvpojUyS_5CsS5BcWOt1_n_UP_dswPA
CitedBy_id crossref_primary_10_3389_fonc_2024_1324859
Cites_doi 10.1182/blood-2010-05-284968
10.1200/JCO.2019.37.15_suppl.7504
10.1158/1078-0432.CCR-19-1251
10.1016/j.apsb.2019.09.006
10.1016/S1470-2045(13)70587-4
10.1186/s13045-018-0559-7
10.1016/j.gde.2012.02.008
10.1016/j.immuni.2020.04.014
10.2217/pgs-2017-0061
10.1016/j.jaci.2018.07.014
10.1111/j.1365-2141.2010.08301.x
10.1038/leu.2012.31
10.1111/ejh.12722
10.1080/10428194.2019.1691195
10.1182/blood-2018-99-113712
10.1016/j.gpb.2016.11.003
10.1101/gad.186411.111
10.1038/s41423-020-0505-9
10.1182/blood-2016-12-756841
10.1182/blood-2021-147169
10.1182/blood-2018-99-114763
10.1053/j.gastro.2018.08.030
10.1182/blood-2007-10-117762
10.1182/blood.2020007702
10.1038/nm.2651
10.1038/leu.2011.278
10.1002/ajh.23778
10.1016/j.leukres.2008.07.003
10.1146/annurev-immunol-041015-055318
10.1097/CCO.0000000000000900
10.1158/0008-5472.CAN-15-1082
10.1056/NEJMra052603
10.1182/blood.2019002038
10.2147/CMAR.S242903
ContentType Journal Article
Copyright Copyright © 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang.
Copyright © 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang. 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang
Copyright_xml – notice: Copyright © 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang.
– notice: Copyright © 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang. 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2023.1051305
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Song et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_5c0ab6bca1034f6b972e539ab5808868
PMC9981645
36873995
10_3389_fphar_2023_1051305
Genre Case Reports
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c468t-c3f81b59a31c9afd43a5607b7915bf98222dd3cf7e48b7e094b90a44abf427003
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:10:47 EDT 2025
Thu Aug 21 18:38:24 EDT 2025
Fri Jul 11 10:05:50 EDT 2025
Mon Jul 21 05:54:07 EDT 2025
Tue Jul 01 02:33:56 EDT 2025
Thu Apr 24 23:03:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords case report
anti-programmed cell death protein 1
chemo-free maintenance therapy
literature review
histone deacetylase inhibitor
T-cell acute lymphoblastic leukemia
Language English
License Copyright © 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-c3f81b59a31c9afd43a5607b7915bf98222dd3cf7e48b7e094b90a44abf427003
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Edited by: Cody J. Peer, National Cancer Institute (NIH), United States
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Reviewed by: Keith Schmidt, National Institutes of Health (NIH), United States
Xiuli Wu, Jinan University, China
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2023.1051305
PMID 36873995
PQID 2783791821
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_5c0ab6bca1034f6b972e539ab5808868
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9981645
proquest_miscellaneous_2783791821
pubmed_primary_36873995
crossref_primary_10_3389_fphar_2023_1051305
crossref_citationtrail_10_3389_fphar_2023_1051305
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-17
PublicationDateYYYYMMDD 2023-02-17
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-17
  day: 17
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Beltra (B4) 2020; 52
dos Santos (B8) 2009; 33
Rudin (B21) 2017; 15
Leoncin (B13) 2022; 34
Tao (B28) 2019; 37
Teachey (B29) 2021; 137
Bachy (B2) 2013; 15
Chen (B7) 2020; 10
Stumpel (B27) 2012; 26
Shi (B25) 2017; 18
Kwong (B12) 2017; 129
Ji (B10) 2018; 132
Guan (B9) 2019; 61
Burke (B5) 2014; 89
Li (B14) 2018; 11
Ntziachristos (B18) 2012; 18
Yan (B31) 2021; 138
Sandoval (B22) 2012; 22
Bassan (B3) 2016; 96
Burke (B35) 2020; 26
Ngiow (B17) 2015; 75
Scuto (B24) 2008; 111
Chen (B6) 2020; 12
Kim (B11) 2018; 155
Bachmann (B1) 2010; 116
Pui (B20) 2006; 354
Schmidl (B23) 2018; 142
Simon (B26) 2012; 26
McLane (B15) 2015; 37
Pan (B19) 2020; 17
Moreno (B16) 2010; 150
Rauch (B33) 2019; 134
Zhou (B32) 2018; 132
Vilas-Zornoza (B30) 2012; 26
References_xml – volume: 116
  start-page: 3013
  year: 2010
  ident: B1
  article-title: Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
  publication-title: Blood
  doi: 10.1182/blood-2010-05-284968
– volume: 37
  start-page: 7504
  year: 2019
  ident: B28
  article-title: Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKtl): A multicenter, single-arm, phase 2 trial (ORIENT-4)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.15_suppl.7504
– volume: 26
  start-page: 2297
  year: 2020
  ident: B35
  article-title: Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: A TACL pilot study
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1251
– volume: 10
  start-page: 723
  year: 2020
  ident: B7
  article-title: Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2019.09.006
– volume: 15
  start-page: 7
  year: 2013
  ident: B2
  article-title: Anti-PD1 antibody: A new approach to treatment of lymphomas
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(13)70587-4
– volume: 11
  start-page: 15
  year: 2018
  ident: B14
  article-title: Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-018-0559-7
– volume: 22
  start-page: 50
  year: 2012
  ident: B22
  article-title: Cancer epigenomics: Beyond genomics
  publication-title: Curr. Opin. Genet. Dev.
  doi: 10.1016/j.gde.2012.02.008
– volume: 52
  start-page: 825
  year: 2020
  ident: B4
  article-title: Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.04.014
– volume: 18
  start-page: 1259
  year: 2017
  ident: B25
  article-title: Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs-2017-0061
– volume: 142
  start-page: 728
  year: 2018
  ident: B23
  article-title: Epigenetic mechanisms regulating T-cell responses
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2018.07.014
– volume: 150
  start-page: 665
  year: 2010
  ident: B16
  article-title: Research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.2010.08301.x
– volume: 26
  start-page: 1517
  year: 2012
  ident: B30
  article-title: Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2012.31
– volume: 96
  start-page: 447
  year: 2016
  ident: B3
  article-title: Lymphoblastic lymphoma: An updated review on biology, diagnosis, and treatment
  publication-title: Eur. J. Haematol.
  doi: 10.1111/ejh.12722
– volume: 61
  start-page: 855
  year: 2019
  ident: B9
  article-title: Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia
  publication-title: Leukemia Lymphoma
  doi: 10.1080/10428194.2019.1691195
– volume: 132
  start-page: 4011
  year: 2018
  ident: B32
  article-title: A novel oral histone deacetylase inhibitor chidamide is highly effective and well-tolerated in adult early T-cell precursor and ph-like acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2018-99-113712
– volume: 15
  start-page: 82
  year: 2017
  ident: B21
  article-title: The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment
  publication-title: Genomics, Proteomics Bioinforma.
  doi: 10.1016/j.gpb.2016.11.003
– volume: 26
  start-page: 651
  year: 2012
  ident: B26
  article-title: A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
  publication-title: Genes and Dev.
  doi: 10.1101/gad.186411.111
– volume: 17
  start-page: 940
  year: 2020
  ident: B19
  article-title: Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment
  publication-title: Cell Mol. Immunol.
  doi: 10.1038/s41423-020-0505-9
– volume: 129
  start-page: 2437
  year: 2017
  ident: B12
  article-title: PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
  publication-title: Blood
  doi: 10.1182/blood-2016-12-756841
– volume: 138
  start-page: 137
  year: 2021
  ident: B31
  article-title: Novel induction therapy for newly diagnosed extranodal natural killer/T cell lymphoma (ENKTL) treated by anti-PD-1 antibody plus histone deacetylase inhibitor followed by P-GemOx regimen
  publication-title: Blood
  doi: 10.1182/blood-2021-147169
– volume: 132
  start-page: 3366
  year: 2018
  ident: B10
  article-title: Chidamide-containing conditioning allogenic hematopoietic stem cell transplantation improves prognosis of acute lymphoblastic leukemia with pre-transplant response less than complete remission
  publication-title: Blood
  doi: 10.1182/blood-2018-99-114763
– volume: 155
  start-page: 1936
  year: 2018
  ident: B11
  article-title: Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.08.030
– volume: 111
  start-page: 5093
  year: 2008
  ident: B24
  article-title: The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells
  publication-title: Blood
  doi: 10.1182/blood-2007-10-117762
– volume: 137
  start-page: 168
  year: 2021
  ident: B29
  article-title: Optimizing therapy in the modern age: Differences in length of maintenance therapy in acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood.2020007702
– volume: 18
  start-page: 298
  year: 2012
  ident: B18
  article-title: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
  publication-title: Nat. Med.
  doi: 10.1038/nm.2651
– volume: 26
  start-page: 682
  year: 2012
  ident: B27
  article-title: Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2011.278
– volume: 89
  start-page: 889
  year: 2014
  ident: B5
  article-title: A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia
  publication-title: Am. J. Hematol.
  doi: 10.1002/ajh.23778
– volume: 33
  start-page: 218
  year: 2009
  ident: B8
  article-title: Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells
  publication-title: Leukemia Res.
  doi: 10.1016/j.leukres.2008.07.003
– volume: 37
  start-page: 457
  year: 2015
  ident: B15
  article-title: CD8 T cell exhaustion during chronic viral infection and cancer
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-041015-055318
– volume: 34
  start-page: 738
  year: 2022
  ident: B13
  article-title: Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: From current standards to precision medicine
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/CCO.0000000000000900
– volume: 75
  start-page: 3800
  year: 2015
  ident: B17
  article-title: A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-1082
– volume: 354
  start-page: 166
  year: 2006
  ident: B20
  article-title: Treatment of acute lymphoblastic leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra052603
– volume: 134
  start-page: 1406
  year: 2019
  ident: B33
  article-title: Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade
  publication-title: Blood
  doi: 10.1182/blood.2019002038
– volume: 12
  start-page: 3003
  year: 2020
  ident: B6
  article-title: Clinicopathological characteristics and mutational profiling of adult T-cell lymphoblastic lymphoma in a Chinese population
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S242903
SSID ssj0000399364
Score 2.3125205
Snippet Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1051305
SubjectTerms anti-programmed cell death protein 1
case report
chemo-free maintenance therapy
histone deacetylase inhibitor
literature review
Pharmacology
T-cell acute lymphoblastic leukemia
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lb9QwEIAt1BMXBKVAoKCphHqhUZP4kZhbQVQVB9TDVuotsp2xumKbXbW7h_33zMTpdhchuHDdPNaaGXtmYs83QnysZEByTDG3FC_nqlO0Dgar88agNRplKONA-_xhLq7U92t9vdXqi8-EJTxwEtypDoXzxgdXFlJF421doZbWed3QBDFDmS_5vK1kaliD2e8alapkKAuzp3Fx45j_WUlubUsrt97xRAOw_09R5u-HJbe8z_lz8WwMG-EsDfeFeIL9vji-TNzp9QlMHsuo7k_gGC4fidTrl2LBWIB5Hu8Q4dYxIYIxGwip-GoN0x4GDgdMcv6QDy6slgizNWl67im8prfCDFc_8XbqPsMZBHJ9kHYbwPUdzDZsZkilMAfi6vzb5OtFPrZayIMyzTIPMlL8qq2TZbAudko6CoVqX9tS-8iMv6rrZIg1qsbXSDmht4VTyvmoeOtavhJ7_bzHNwJqjdZWWGClvOpM4YKrSHm8gYienshE-SD2Nowccm6HMWspH2FVtYOqWlZVO6oqE582zywSheOvd39hbW7uZIL28APZVTvaVfsvu8rE0YMttDTjWPqux_nqvuXeJCSXpioz8TrZxuavpGlqLhbORL1jNTtj2b3ST28GqjflvZS66rf_Y_DvxFMWCJ8uL-tDsbe8W-F7Cp6W_sMwT34BuDoZFQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review
URI https://www.ncbi.nlm.nih.gov/pubmed/36873995
https://www.proquest.com/docview/2783791821
https://pubmed.ncbi.nlm.nih.gov/PMC9981645
https://doaj.org/article/5c0ab6bca1034f6b972e539ab5808868
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZKuXBBvFkelZFQLzSwie04RkKoIKoKCdTDrtRbZDtjuiJNln1I5N8z42S3LCqcuCZ2Ys14PN_Ynm8Ye5kJD-iYQmIQLyeykrgOeqOSIgeTKxA-DZHt82t-OpWfz9X5HtuUOxoEuLw2tKN6UtNF_frnj-49Gvw7ijjR374J8wtL1J6ZoKq1uCirG-wmeiZNFQ2-DHA_rszkjXPZ5878peuOf4o0_tdhzz-vUP7mk07usNsDmOTHvfbvsj1o7rHDs56Nujvik6vkquURP-RnVzzV3X02J7KANgkLAH5piTeCyDeA9ylZHZ81PLJz8ElC2_vc-vUKeN2h_luHoBu_ymtYf4fLmX3Lj7lHh8j7Mwhum4rXW8Zm3ifIPGDTk0-Tj6fJUIAh8TIvVokXAVGtMlak3thQSWERIGmnTapcIOa_rKqEDxpk4TRgpOjM2EppXZB0oC0esv2mbeAx41qBMRmMIZNOVvnYepvZNB4rgsMeI5ZuxF76gZ2cimTUJUYppKoyqqokVZWDqkbs1bbPvOfm-GfrD6TNbUvi1Y4P2sW3cjDTUvmxdbnzODQhQ-6MzkAJY50qcDnOixF7sZkLJdohSd820K6XJVUsQbkUWTpij_q5sf2VyAtNKcQjpndmzc5Ydt80s4vI9Y3RMAa06sn_GPxTdosEQnfOU_2M7a8Wa3iOkGrlDuJWxEG0ll8GPyKt
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chemo-free+maintenance+therapy+in+adult+T-cell+acute+lymphoblastic+leukemia%3A+A+case+report+and+literature+review&rft.jtitle=Frontiers+in+pharmacology&rft.au=Yuanbin+Song&rft.au=Shuzhao+Chen&rft.au=Chenfei+Liu&rft.au=Lezong+Chen&rft.date=2023-02-17&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=14&rft_id=info:doi/10.3389%2Ffphar.2023.1051305&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5c0ab6bca1034f6b972e539ab5808868
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon